Nektar Therapeutics
Nektar Therapeutics (NKTR) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NKTR · as of Jun 8, 2026
Key Statistics
Explore Nektar Therapeutics Data
nktr stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 33 · Buy rate: 66.7%
The NKTR analyst consensus is Buy, based on ratings from 33 Wall Street analysts over the past 3 months. The average 12-month price target is $149.60, representing +164.22% upside from the current price of $56.62.
Competitors & Peers
nktr competitorsNKTR
AMLX
ATAI
ELVN
IMTX
INBXStock Performance
Full HistoryAbout Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bemp…
what is nektar therapeutics · nktr stock overview · nektar therapeutics company profile · who is nektar therapeutics ceo · nktr NASDAQ · nektar therapeutics headquarters · nektar therapeutics business segments
About Stock Overview & Key Data
Nektar Therapeutics (NKTR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 3, 1994. As of the latest trading session, NKTR stock price is $56.62, with a market capitalization of $1.1B. The stock has returned +534.13% over the past 12 months and +31.84% year-to-date.
According to 33 Wall Street analysts, the consensus rating for Nektar Therapeutics stock is Buy, with an average 12-month price target of $149.60. In fiscal year 2025, Nektar Therapeutics reported revenue of $55.2M and net income of -$164.1M. For detailed data — including Nektar Therapeutics revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Nektar Therapeutics (NKTR) stock price is $56.62. The stock is traded on NASDAQ under the ticker symbol NKTR. The 52-week range is $7.99 – $109.00.